Ask AI
ProCE Banner Activity

CE / CME

Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC

Video

In this certified on-demand webcast, experts discuss quality improvement strategies for systematically identifying patients with high-risk HR-positive/HER2-negative early breast cancer who may benefit from adjuvant CDK4/6 inhibitor therapy, highlighting multidisciplinary workflows, guideline implementation, risk assessment tools, and real-world challenges in integrating clinical trial criteria into practice.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: May 21, 2026

Expiration: May 20, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Q Synthesis and The American Society of Breast Surgeons Foundation.

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Q Synthesis LLC

ProCE Banner

The American Society of Breast Surgeons Foundation

ProCE Banner

Target Audience

Oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with HR-positive/HER2-negative EBC within 3 community cancer centers and extended to a similar cohort of healthcare professionals across the United States.

Program Learning Goal

The goal of this activity is to improve knowledge, competence, and confidence of learners to assess patients with HR+/HER2- early stage breast cancer for high-risk features and implement optimal therapeutic strategies to reduce the risk of recurrence. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize factors used to assess risk of recurrence in patients with HR+/HER2- EBC

  • Identify patients with high-risk HR+/HER2- EBC

  • Communicate assessment of risk and associated clinical and therapeutic implications to patients

  • Select guideline recommended adjuvant therapy for patients with HR+/HER2- EBC considering the patient’s risk of recurrence 

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Amy Baker, APRN, CNS-BS, AOCNS, has no relevant financial relationships to disclose.

Alicia Heelan, MD, MS, FACS, FSSO: consultant/advisor/speaker: Elucent Medical.

Joseph Kim, MD, MPH, MBA, has no relevant financial relationships to disclose.

Sarah Snell, MD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Decera Clinical Education, Q Synthesis, and the American Society of Breast Surgeons Foundation do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:

Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 21, 2026, through May 20, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education, Q Synthesis, and the American Society of Breast Surgeons Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-9999-26-317-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 20, 2027. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to ​1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.​

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. ​

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME for MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.

IPCE Credit Designation

A logo for a credit companyAI-generated content may be incorrect.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.